Skip to main content
An image of the WATCHMAN FLX Pro device on a teal background.

featuring HEMOCOAT™ Technology

WATCHMAN FLX™ Pro

Left Atrial Appendage Closure Device

Clinical Data

Recent studies

Pre-clinical data

The fluoropolymer-coated WATCHMAN FLX Pro device showed significantly less thrombus and reduced inflammation in a challenging canine model. Mechanistic studies demonstrated that the WATCHMAN FLX Pro device binds more albumin, leading to reduced platelet activation, less inflammation, and greater endothelial coverage (EC).1

Learn more about WATCHMAN FLX Pro

References

1. Saliba et al. Enhanced Thromboresistance and Endothelialization of a Novel Fluoropolymer-Coated Left Atrial Appendage Closure Device, JACC: Clinical Electrophysiology, 2023.